GlassScriptPhysician profile
David B Sanford
NPI 1629039342
$4,588.51
in general payments reported to CMS, 2019-2025
53 companies · $2,445 in 2025
The $2,445 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $245 · 2021: $177 · 2022: $304 · 2023: $284 · 2024: $793 · 2025: $2,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,211 · Grant: $235 · Education: $75.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,211.08 |
| Grant | $235.20 |
| Education | $75.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $539.82 | 2019-2025 | Rybrevant, Darzalex, Erleada |
| E.R. Squibb & Sons, L.L.C. | $504.27 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $282.89 | 2023-2025 | Imfinzi, Enhertu, Lynparza |
| Abbvie INC. | $235.20 | 2025 | |
| Pfizer INC. | $186.92 | 2019-2025 | |
| Springworks Therapeutics, INC. | $165.77 | 2024-2025 | Ogsiveo, Gomekli |
| Beigene USA, INC. | $156.87 | 2023-2025 | Brukinsa |
| Merck Sharp & Dohme LLC | $156.08 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $147.08 | 2022-2025 | Reblozyl, Onureg |
| Novartis Pharmaceuticals Corporation | $136.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $122.40 | 2024-2025 | Ojjaara, Blenrep |
| Kite Pharma, INC. | $109.95 | 2020-2025 | Yescarta |
| Incyte Corporation | $100.32 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
| Tersera Therapeutics LLC | $93.53 | 2025 | Xermelo, Zoladex |
| Genzyme Corporation | $92.10 | 2020-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $91.31 | 2019-2025 | Vyloy |
| Daiichi Sankyo INC. | $83.78 | 2024-2025 | Enhertu |
| Rigel Pharmaceuticals, INC. | $82.89 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Gilead Sciences, INC. | $77.71 | 2019-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $75.82 | 2025 | |
| Apellis Pharmaceuticals, INC. | $75.56 | 2024 | Empaveli |
| Sobi, INC | $62.11 | 2025 | |
| Geron Corporation | $61.36 | 2025 | Rytelo |
| Spectrum Pharmaceuticals INC. | $61.34 | 2025 | Rolvedon |
| Aveo Pharmaceuticals, INC. | $59.48 | 2022-2025 | |
| Sirtex Medical INC | $56.46 | 2023-2025 | Sir-Spheres Microspheres |
| Tempus Ai, INC | $51.92 | 2024-2025 | Xt Cdx |
| Secura Bio, INC. | $48.78 | 2020-2024 | Copiktra |
| Beone Medicines USA, INC. | $48.64 | 2025 | Brukinsa |
| Eisai INC. | $43.93 | 2021-2025 | |
| Stemline Therapeutics INC. | $41.55 | 2024-2025 | Orserdu |
| Corcept Therapeutics | $39.75 | 2025 | Korlym |
| Lilly USA, LLC | $38.35 | 2020-2025 | Verzenio, Jaypirca |
| Exelixis INC. | $36.73 | 2024-2025 | Cabometyx |
| Pharmaessentia USA Corporation | $30.50 | 2024 | Besremi |
| Boston Scientific Corporation | $28.94 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Taiho Oncology, INC. | $27.83 | 2024 | |
| Agios Pharmaceuticals, INC. | $27.77 | 2019-2025 | Pyrukynd |
| Syndax Pharmaceuticals, INC. | $27.05 | 2025 | |
| Recordati_rare_diseases_inc. | $25.17 | 2025 | Enjaymo |
| Verity Pharmaceuticals INC. | $22.91 | 2022 | |
| Sumitomo Pharma America, INC. | $22.81 | 2025 | Orgovyx |
| Jazz Pharmaceuticals INC. | $22.54 | 2022 | |
| Genentech USA, INC. | $21.96 | 2025 | Venclexta |
| Adc Therapeutics America, INC. | $21.58 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $21.45 | 2019 | |
| Puma Biotechnology, INC. | $20.41 | 2025 | |
| Servier Pharmaceuticals LLC | $19.97 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.93 | 2024 | Alunbrig |
| Acceleron Pharma, INC. | $17.61 | 2020 | |
| Caris Mpi, INC. | $16.19 | 2025 | Mi Cancer Seek |
| Karyopharm Therapeutics INC. | $14.06 | 2025 | Xpovio |
| Amgen INC. | $13.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sanford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.